A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
Clinical trial NCT06503679 · COMPLETED
Trial details
- NCT number
- NCT06503679
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-16
- Primary completion
- 2024-12-31
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.